Development of Mechanism-Based Anticancer Therapy

描述(由申请人提供)：这个职业发展奖的目的是获得支持，以设计和进行临床试验，利用新的，基于机制的代理，同时也指导研究员和初级教员在早期临床试验研究学科。临床和转化性研究的总体目标是开发针对特定生物学改变的治疗结直肠癌的新方案，从而产生不仅比目前的化疗方案更有效，而且毒性可能更低的策略。该研究建议的具体目的是：1)建立使用双血管内皮生长因子受体和表皮生长因子受体酪氨酸激酶抑制剂ZD6474、化疗和塞来昔布同时针对肿瘤和内皮细胞的结直肠癌临床前机制治疗模型；2)开发影响信号转导和促生存因素的新型靶向药物组合，作为最佳疗效后治疗结直肠癌的潜在维持方案；3)在转移性结直肠癌患者中临床测试特定目标1和2中开发的方案，包括详细的药理学、生物学和影像研究，以评估药物暴露、生物效果和患者利益之间的关系。这些具体目标反映了首席调查员感兴趣的领域和专门知识，并表明了这项提议将资助的以假设为导向的研究的重点。为了促进医生在高质量面向患者的研究方面的培训，首席研究员将继续开展发展治疗学的培训和指导计划，该计划将利用上述具体目标和重点课程作为一种手段，促进研究员和初级教员在疾病导向的临床和转化性癌症研究方面的职业生涯。

DESCRIPTION (provided by applicant): The purpose of this career development award is to obtain support to design and conduct clinical trials that utilize novel, mechanism-based agents while also mentoring fellows and junior faculty in the discipline of early clinical trials research. The overall objective of the clinical and translational research is to develop novel regimens for the treatment of colorectal cancer that target specific biological alterations thereby resulting in strategies that are not only more effective, but also potentially less toxic than current chemotherapy regimens. The Specific Aims of the research proposal are to: 1) Develop preclinical models of mechanism-based therapy for colorectal cancer that targets both tumor and endothelial cells using the dual VEGF-R and EGF-R tyrosine kinase inhibitor, ZD6474, chemotherapy, and celecoxib, 2) Develop novel combinations of targeted agents (without chemotherapy) that impact upon signal transduction and pro-survival factors as potential maintenance regimens in CRC after best response, and 3) Clinically test the regimens developed in Specific Aims 1 and 2 in patients with metastatic CRC, incorporating detailed pharmacological, biological and imaging studies to assess the relationships between drug exposure, biological effect and patient benefit. These Specific Aims reflect the areas of interest and expertise of the Principal Investigator and demonstrate the focus of hypothesis-driven research that would be funded by this proposal. To facilitate the training of physicians in high quality patient-oriented research, the Principal Investigator will continue a training and mentoring program in Developmental Therapeutics which will utilize the above Specific Aims and a focused curriculum as a means to advance the careers of fellows and junior faculty in disease-directed clinical and translational cancer research.